RANKL inhibition for the management of patients with benign metabolic bone disorders. (Q37532561)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

RANKL inhibition for the management of patients with benign metabolic bone disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Athanasios D Anastasilakis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Konstantinos A Toulis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Evangelos Terpos

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1085-1102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Adverse outcomes of osteoporotic fractures in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Treatment of premenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum levels of osteoprotegerin increase with age in a healthy adult population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Correlates of osteoprotegerin levels in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Soluble RANKL and risk of nontraumatic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

PTH differentially regulates expression of RANKL and OPG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

In vivo administration of 1,25‐dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The role of the receptor activator of nuclear factor-kappaB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The RANKL/OPG system and bone mineral density in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Imbalance of osteoclastogenesis-regulating factors in patients with celiac disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin deficiency and juvenile Paget's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effect of EstrogenversusTestosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Botox induced muscle paralysis rapidly degrades bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Regulatory effects of osteoprotegerin on cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Severely suppressed bone turnover and atypical skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Mutation Screening of the TNFRSF11A Gene Encoding Receptor Activator of NFkB (RANK) in Familial and Sporadic Paget's Disease of Bone and Osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903048929

10.1517/13543780903048929

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558335%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference